Thus, not only the bacterial adaptation to each patient and specific niche (bloodstream/CF lung) but also the complex modes of action of lysozyme and PGLYRPs could contribute to generate particularities among the studied treatments/strains. This evidence concerns the gene LYZ and cystic fibrosis.